tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Prelude Therapeutics sees cash runway into 2Q26

Cash, cash equivalents and marketable securities as of December 31, 2024 were $133.6M. The Company anticipates that its existing cash, cash equivalents and marketable securities will fund Prelude’s operations into the second quarter of 2026.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1